Intravitreal aflibercept for diabetic macular edema.

By J. Korobelnik, D. Do, Ursula Schmidt-Erfurth, D. Boyer, F. Holz, J. Heier, E. Midena, P. Kaiser, H. Terasaki, D. Marcus and 13 more. Ophthalmology (Rochester, Minn.), 2014

842 citations recorded by the source corpus.

Subfields: Ophthalmology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/052c97c4b630d62871fa4603c1906aa04acd28b2

Citations in the corpus

• Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial (2016, neutral): “of participants (%) Nonfatal myocardial infarction 7 (3) 3 (1) 6 (3) Nonfatal stroke 2 (<1) 6 (3) 11 (5) Vascular death (from any potential vascular or unknown cause) 3 (1) 8 (4) 9 (4) Any Antiplatelet Trialists’ Collaboration Event 12 (5) 17 (8) 26 (12) 0.”